Is Bolt Biotherapeutics, Inc. overvalued or undervalued?

As of 30 March 2022, the valuation grade for Bolt Biotherapeutics, Inc. moved from does not qualify to risky, indicating increased scrutiny regarding its financial health. The company appears to be overvalued, particularly given its negative performance metrics. Key ratios such as the Price to Book Value at 0.26, EV to EBIT at 0.39, and EV to EBITDA at 0.40 highlight significant concerns about its valuation relative to its financial performance.
In comparison to its peers, Bolt Biotherapeutics has a P/E ratio of -0.1998, while Assembly Biosciences, Inc. and Fortress Biotech, Inc. show even more negative valuations at -9.3127 and -1.1589, respectively. This suggests that while Bolt is not alone in its struggles, it still faces substantial challenges. Over the past year, Bolt Biotherapeutics has underperformed significantly, with a return of -57.46% compared to the S&P 500's gain of 17.14%, reinforcing the notion that the stock is overvalued in its current state.